JMM Profile: Fosfomycin: a potential antibiotic for multi- and extensively resistant bacteria

References

1. Hendlin D, Stapley EO, Jackson M, Wallick H, Miller AK et al. Phosphonomycin, a new antibiotic produced by strains of Streptomyces. Science 1969; 166:122–123 [View Article]
   [Google Scholar]
2. Carlone NA, Borsotto M, Cuffini AM, Savoia D. Effect of fosfomycin trometamol on bacterial adhesion in comparison with other chemotherapeutic agents. Eur Urol 1987; 13 Suppl 1:86–91 [View Article]
   [Google Scholar]
3. Yokota S, Okabayashi T, Yoto Y, Hori T, Tsutsumi H et al. Fosfomycin suppresses RS-virus-induced Streptococcus pneumoniae and Haemophilus influenzae adhesion to respiratory epithelial cells via the platelet-activating factor receptor. FEMS Microbiol Lett 2010; 310:84–90 [View Article]
   [Google Scholar]
4. Silver LL. Fosfomycin: mechanism and resistance. Cold Spring Harb Perspect Med 2017; 7: [View Article]
   [Google Scholar]
5. De Smet KAL, Kempsell KE, Gallagher A, Duncan K, Young DB. Alteration of a single amino acid residue reverses fosfomycin resistance of recombinant MurA from Mycobacterium tuberculosis. Microbiology 1999; 145:3177–3184 [View Article]
   [Google Scholar]
6. McCoy AJ, Sandlin RC, Maurelli AT. In vitro and in vivo functional activity of Chlamydia MurA, a UDP-N-acetylglucosamine enolpyruvyl transferase involved in peptidoglycan synthesis and fosfomycin resistance. J Bacteriol 2003; 185:1218–1228 [View Article]
   [Google Scholar]
7. Borisova M, Gisin J, Mayer C. Blocking peptidoglycan recycling in Pseudomonas aeruginosa attenuates intrinsic resistance to fosfomycin. Microb Drug Resist 2014; 20:231–237 [View Article]
   [Google Scholar]
8. Gil-Marqués ML, Moreno-Martínez P, Costas C, Pachón J, Blázquez J et al. Peptidoglycan recycling contributes to intrinsic resistance to fosfomycin in Acinetobacter baumannii. J Antimicrob Chemother 2018; 73:2960–2968 [View Article]
   [Google Scholar]
9. Li X, Quan J, Yang Y, Ji J, Liu L et al. Abrp, a new gene, confers reduced susceptibility to tetracycline, glycylcine, chloramphenicol and fosfomycin classes in Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 2016; 35:1371–1375 [View Article]
   [Google Scholar]
10. Alper MD, Ames BN. Transport of antibiotics and metabolite analogs by systems under cyclic AMP control: positive selection of Salmonella typhimurium cya and crp mutants. J Bacteriol 1978; 133:149–157 [View Article]
    [Google Scholar]
11. Tsuruoka T, Miyata A, Yamada Y. Two kinds of mutants defective in multiple carbohydrate utilization isolated from in vitro fosfomycin-resistant strains of Escherichia coli K--12. J Antibiot 1978; 31:192–201 [View Article]
    [Google Scholar]
12. Venkateswaran PS, Wu HC. Isolation and characterization of a phosphonomycin-resistant mutant of Escherichia coli K-12. J Bacteriol 1972; 110:935–944 [View Article]
    [Google Scholar]
13. Horii T, Kimura T, Sato K, Shibayama K, Ohta M. Emergence of fosfomycin-resistant isolates of Shiga-like toxin-producing Escherichia coli O26. Antimicrob Agents Chemother 1999; 43:789–793 [View Article]
    [Google Scholar]
14. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev 2016; 29:321–347 [View Article]
    [Google Scholar]
15. Guo Q, Tomich AD, McElheny CL, Cooper VS, Stoesser N et al. Glutathione-S-transferase FosA6 of Klebsiella pneumoniae origin conferring fosfomycin resistance in ESBL-producing Escherichia coli. J Antimicrob Chemother 2016; 71:2460–2465 [View Article]
    [Google Scholar]
16. Mathur P, Veeraraghavan B, Devanga Ragupathi NK, Inbanathan FY, Khurana S et al. Multiple mutations in lipid-A modification pathway & novel fosA variants in colistin-resistant Klebsiella pneumoniae. Future Sci OA 2018; 4:FSO319 [View Article]
    [Google Scholar]
17. Pakhomova S, Rife CL, Armstrong RN, Newcomer ME. Structure of fosfomycin resistance protein FosA from transposon Tn2921. Protein Sci 2004; 13:1260–1265 [View Article]
    [Google Scholar]
18. Xu H, Miao V, Kwong W, Xia R, Davies J. Identification of a novel fosfomycin resistance gene (fosA2) in Enterobacter cloacae from the Salmon River, Canada. Lett Appl Microbiol 2011; 52:427–429 [View Article]
    [Google Scholar]
19. Yang TY, Lu PL, Tseng SP. Update on fosfomycin-modified genes in Enterobacteriaceae. J Microbiol Immunol Infect 2019; 52:9–21 [View Article]
    [Google Scholar]
20. Sharma A, Sharma R, Bhattacharyya T, Bhando T, Pathania R. Fosfomycin resistance in Acinetobacter baumannii is mediated by efflux through a major facilitator superfamily (MFS) transporter-AbaF. J Antimicrob Chemother 2017; 72:68–74 [View Article]
    [Google Scholar]
21. Truong-Bolduc QC, Wang Y, Hooper DC. Tet38 efflux pump contributes to fosfomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2018; 62:e00927-18 [View Article]
    [Google Scholar]
22. Trinh TD, Smith JR, Rybak MJ. Parenteral fosfomycin for the treatment of multidrug resistant bacterial infections: the rise of the epoxide. Pharmacotherapy 2019; 39:1077–1094 [View Article]
    [Google Scholar]
23. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the infectious diseases. Soc Am Eur Soc Microbiol Infect Dis Clin Infect Dis 2011; 52:e103–20
    [Google Scholar]
24. Derington CG, Benavides N, Delate T, Fish DN. Multiple-dose oral fosfomycin for treatment of complicated urinary tract infections in the outpatient setting. Open Forum Infect Dis 2020; 7:faa034 [View Article]
    [Google Scholar]
25. Qiao L-D, Zheng B, Chen S, Yang Y, Zhang K et al. Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study. BMJ Open 2013; 3:e004157 [View Article]
    [Google Scholar]
26. Bergan T. Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity. Infection 1990; 18 Suppl 2:S65–9 [View Article]
    [Google Scholar]
27. Matsumoto T, Muratani T, Nakahama C, Tomono K. Clinical effects of 2 days of treatment by fosfomycin calcium for acute uncomplicated cystitis in women. J Infect Chemother 2011; 17:80–86 [View Article]
    [Google Scholar]
28. Kaye KS, Rice LB, Dane AL, Stus V, Sagan O et al. Fosfomycin for injection (ZTI-01) versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, A phase 2/3 randomized trial. Clin Infect Dis 2019; 69:2045–2056 [View Article]
    [Google Scholar]
29. Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem-resistant Enterobacteriaceae infections. Clin Microbiol Infect 2019; 25:943–950 [View Article]
    [Google Scholar]
30. Gisin J, Schneider A, Nägele B, Borisova M, Mayer C. A cell wall recycling shortcut that bypasses peptidoglycan de novo biosynthesis. Nat Chem Biol 2013; 9:491–493 [View Article]
    [Google Scholar]
31. Castañeda-García A, Blázquez J, Rodríguez-Rojas A. Molecular mechanisms and clinical impact of acquired and intrinsic fosfomycin resistance. Antibiotics 2013; 2:217–236 [View Article]
    [Google Scholar]
32. Thompson MK, Keithly ME, Goodman MC, Hammer ND, Cook PD et al. Structure and function of the genomically encoded fosfomycin resistance enzyme, FosB, from Staphylococcus aureus. Biochemistry 2014; 53:755–765 [View Article]
    [Google Scholar]
33. Castañeda-García A, Rodríguez-Rojas A, Guelfo JR, Blázquez J. The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa. J Bacteriol 2009; 191:6968–6974 [View Article]
    [Google Scholar]
34. Kadner RJ, Winkler HH. Isolation and characterization of mutations affecting the transport of hexose phosphates in Escherichia coli. J Bacteriol 1973; 113:895–900 [View Article]
    [Google Scholar]
35. Nilsson AI, Berg OG, Aapevall O, Kahlmeter G, Andersson DI. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 2003; 47:2850–2858 [View Article]
    [Google Scholar]
36. Takahata S, Ida T, Hiraishi T, Sakakibara S, Maebashi K et al. Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int J Antimicrob Agents 2010; 35:333–337 [View Article]
    [Google Scholar]
37. Cao M, Bernat BA, Wang Z, Armstrong RN, Helmann JD. FosB, a cysteine-dependent fosfomycin resistance protein under the control of sigma(W), an extracytoplasmic-function sigma factor in Bacillus subtilis. J Bacteriol 2001; 183:2380–2383 [View Article]
    [Google Scholar]
38. Etienne J, Gerbaud G, Fleurette J, Courvalin P. Characterization of staphylococcal plasmids hybridizing with the fosfomycin resistance gene fosB. FEMS Microbiol Lett 1991; 68:119–122 [View Article]
    [Google Scholar]
39. Qu T, Shi K, Ji J, Yang Q, Du X et al. Fosfomycin resistance among vancomycin-resistant enterococci owing to transfer of a plasmid harbouring the fosB gene. Int J Antimicrob Agents 2014; 43:361–365 [View Article]
    [Google Scholar]
40. Zilhao R, Courvalin P. Nucleotide sequence of the fosB gene conferring fosfomycin resistance in Staphylococcus epidermidis. FEMS Microbiol Lett 1990; 56:267–272 [View Article]
    [Google Scholar]
41. García P, Arca P, Evaristo Suárez J. Product of fosC, a gene from Pseudomonas syringae, mediates fosfomycin resistance by using ATP as cosubstrate. Antimicrob Agents Chemother 1995; 39:1569–1573 [View Article]
    [Google Scholar]
42. Kobayashi S, Kuzuyama T, Seto H. Characterization of the fomA and fomB gene products from Streptomyces wedmorensis, which confer fosfomycin resistance on Escherichia coli. Antimicrob Agents Chemother 2000; 44:647–650 [View Article]
    [Google Scholar]